Dr. Heller’s current research interests include the design and analysis of phase 2 clinical trials, the analysis of survival data, and the investigation of predictive accuracy measures. For the analysis of phase 2 studies, he has developed a test statistic that adjusts for patient risk when the patient population is heterogeneous. This approach is applicable in targeted therapy trials, where multiple patient populations are treated under a single protocol. In survival analysis, he has developed a measure of predictive accuracy, based on the concept of explained randomness. This metric, applied to risk models with survival data, is used to determine the adequacy of a risk classification model for clinical decision making. In addition, he is developing statistical methods to evaluate the improvement in risk classification measures due to the inclusion of new biomarkers. The statistical methods will provide a metric to decide whether a change in patient risk, due to the inclusion of new biomarkers into the risk model, is random variation or a true improvement in the accuracy of a risk classification model. Finally, Dr. Heller is involved in the design and analysis of laboratory and clinical studies emanating from the Departments of Medicine, Pediatrics, and Surgery.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Glenn Heller discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures